#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute hepatic failure Loss of consciousness Dilated cardiomyopathy Adenovirus infection Mycobacterium abscessus infection Non-Hodgkin's lymphoma unspecified histology indolent Oesophageal adenocarcinoma stage II Infantile apnoea Crigler-Najjar syndrome Haemophilia B without inhibitors Arteriovenous malformation Myxofibrosarcoma Glomerulonephritis acute Hereditary neuropathic amyloidosis Nodal marginal zone B-cell lymphoma More trials…

    Learn about Rare Diseases

    Synovial sarcoma recurrent – Life with Disease Erdheim-Chester disease – Diagnostics Behcet’s syndrome – Treatment Cystic fibrosis – Trials in Disease Hyperoxaluria – Treatment Langerhans cell sarcoma – Diagnostics Pleural mesothelioma malignant – Basic Information Glomerulonephritis membranous – Trials in Disease Nephroblastoma – Basic Information Adrenogenital syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tadalafil Azelastine Miglustat EGANELISIB Satoreotide Tetraxetan E2814 Follitropin Delta Levamlodipine Succinate Dextrose Bp [18F]-Altanserin PIPOTIAZINE Nandrolone Decanoate Vx-264 Deucrictibant Ambrisentan WEF-001 ATUMELNANT Obinutuzumab Infliximab Rbl016.2 More therapies…

    Learn about Your Condition

    Fibromyalgia Triple negative breast cancer Gouty arthritis Deafness traumatic Diffuse large B-cell lymphoma Angiosarcoma Haemodialysis Fracture infection Rectal cancer stage II Craniotomy EGFR gene mutation Embolic stroke Pancreatitis relapsing Small intestine adenocarcinoma Elderly More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer metastatic

  • Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    • Prostate cancer
    Investigated Drugs:
    • Capivasertib
    • Docetaxel
    Belgium Czechia France Greece Hungary The Netherlands +2

  • Study on LAVA-1207 and Pembrolizumab for Patients with Advanced Prostate Cancer Resistant to Treatment

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Humanised Bispecific Immunoglobulin Vhh Fragments Against Psma And Vgamma9Vdelta2 T-Cell Receptor
    • Pembrolizumab
    The Netherlands Spain

  • Study on the Effectiveness and Safety of Apalutamide, Abiraterone Acetate, and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Abiraterone Acetate
    • Apalutamide
    • Prednisone
    Germany The Netherlands Spain

  • Study on the Safety and Effects of AZD5305 with Hormonal Agents for Patients with Metastatic Prostate Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    • Darolutamide
    Italy

  • Study on the Effectiveness of Apalutamide in Men with Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Abiraterone Acetate
    • Apalutamide
    • Prednisone
    Austria Belgium Czechia Denmark France Germany +6

  • Study of Apalutamide and Androgen Deprivation Therapy for Patients with Metastatic Hormone-sensitive Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Apalutamide
    Czechia Romania Spain
Previous Page
1 … 4 5 6 7 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!